Context: Primary hyperparathyroidism reduces bone mineral density, which increases the risk of fracture.
| INTRODUC TI ON
Primary hyperparathyroidism (PHPT) is the autonomous overproduction of parathormone (PTH) owing to hyperfunction of 1 or more parathyroid glands. It can be caused by a single-gland adenoma, multigland hyperplasia or parathyroid carcinoma. 1, 2 PHPT is the third most common endocrine disorder and the most common cause of hypercalcemia in outpatients. 2, 3 Its prevalence is about 1 to 4 per 1000 in the United States, and it occurs in about 3 times as many women as men. [2] [3] [4] The incidence of PHPT rises with age, peaking in women between 50 and 60 years old. 2 The classic clinical presentation of PHPT is often characterized as "bones, stones, groans, and psychiatric overtones," but since the 1970s, the availability of routine calcium testing and PTH assays has improved the recognition of PHPT and allowed earlier diagnosis with little or no symptoms. 1, 2, 4 Parathyroidectomy (PTX) remains the only definitive curative treatment for PHPT. 1, 5, 6 Recent guidelines issued by the American Association of Endocrine Surgeons clearly and objectively define the indications for PTX. 1 Observation and pharmacologic therapy are less clinically effective and less cost-effective than surgical intervention, even in patients with seemingly mild disease. 1 Primary hyperparathyroidism is a secondary cause of osteoporosis; it causes increased bone turnover, a subsequent reduction in bone mineral density (BMD), and thus a predisposition towards fractures. [7] [8] [9] The economic impact of osteoporosis on the health care system is estimated to be $50 billion by the year 2040 in the United States. 10 Men account for one-third of all patients with osteoporotic fractures worldwide and at age 60 have a lifetime fracture risk as high as 29%.
11,12
When a fracture is present, secondary osteoporosis is estimated to occur in up to 60% of men and 30% of women. 11, [13] [14] [15] Men account for at least one-third of all hip fractures, and the worldwide incidence of hip fracture is estimated to increase by 310% in men vs 240% in women by 2050. 16, 17 A 50-year-old man has an estimated 17% chance of experiencing a hip fracture during his lifetime, and this risk rises to 25% by age 60. 10 One year after a hip fracture, only 20% of men return to their prefracture level of function. 10 Although the overall prevalence of fragility fractures is higher in women, men are reported to have higher rates of fracture-related mortality after hip fracture from the in-hospital period all the way to 6 months, 1 year, 5 years and 7 years 10, 11, 16, [18] [19] [20] [21] [22] [23] These higher rates of mortality in men are thought to be attributable to men's having higher rates of comorbidity than women. 16, 24 Multiple studies have found that surgical intervention for sporadic PHPT (sPHPT) is associated with an increase in postoperative BMD, 2, 3, [5] [6] [7] [8] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] but only a few studies have examined gender differences in BMD improvement after PTX. 8, 10, 25 In this retrospective study, we aimed to determine differences in laboratory data and BMD changes after PTX between men and women (both premenopausal [pre-MP] and postmenopausal [post-MP]) with sPHPT.
We hypothesized that after surgical intervention, there would be a similar increase in BMD between genders, emphasizing the direct impact of PTX in restoration of bone mineralization in the postoperative period. min/1.73 m²), 25-hydroxy vitamin D (normal range, 20-52 ng/mL) and 24-hour urinary calcium levels (normal rage, 50-150 mg/dL) were gathered.
| PATIENTS AND ME THODS

| Patients
| Biochemical analysis
| Dual-energy X-ray absorptiometry
Dual-energy X-ray absorptiometry scans were performed using a Discovery DXA system or QDR 4500w densitometer (Hologic, 
| Statistical analysis
| RE SULTS
Eighty patients met all inclusion criteria and had both preoperative and postoperative DXA scans available for review. This represented 5.2% of the total population of 1529 patients with PHPT who underwent PTX in our institution during the study period. We excluded 1449 of these patients from the study for the reasons noted in Figure 1 . Among the 80 included patients, 24 (30%) were men and 56 (70%) were women. Among the women, 10 were pre-MP and 46
were post-MP.
| Demographic comparisons
The patients' demographic data are shown in Table 1 . The age at sPHPT diagnosis and age at PTX were similar in men and all women (P = 0.32 and P = 0.36, respectively). Pre-MP women were significantly younger at diagnosis and PTX than were men (P = 0.0017
and P = 0.0014, respectively), whereas post-MP women were significantly older than men (P = 0.03 and P = 0.03, respectively).
The time from diagnosis to surgical intervention was significantly longer in post-MP women than in men (P = 0.04). We found no differences in body mass index or ethnicity (White, Black, Hispanic and Asian) among the 4 study groups.
| Biochemical measurements
There were no significant differences between the 4 comparison groups in the following preoperative laboratory values: serum calcium, serum corrected calcium, serum intact PTH, 25-hydroxy vitamin D and GFR. However, preoperative serum creatinine and 24-hour urinary calcium levels were significantly higher in men than in women overall (P = 0.0002 and P = 0.02, respectively) and post-MP women (P < 0.0001 and P = 0.01, respectively). Biochemical assessments at 6 months post-PTX showed significant differences only in corrected serum calcium levels, which were lower in men than women overall (P = 0.01) and post-MP women (P = 0.01). No differences were found in the laboratory values of pre-MP and post-MP women ( Table 2 ).
| Preoperative Z-scores
The preoperative Z-scores are shown in Figure 2 . Men had marginally lower preoperative Z-scores than women at the LS (P = 0.06).
The FN Z-score was lower in men than in women overall (P = 0.0018), 
| BMD change after parathyroidectomy
The percentages of change in BMD from baseline to 12 ± 6 months after PTX are shown in 
| D ISCUSS I ON
The current study reveals that men have greater bone mineral density increase after PTX than women and that this increase cannot be attributed to hormonal variations between genders, as gains in incidence of disease 37 which were not the purpose of our study.
In our cohort, men had lower preoperative Z-scores than did women at all 4 anatomical sites, suggesting that men were more affected by bone disease before PTX. This difference could be attributable to a delay in seeking medical care or in diagnosis. It is thought that women see primary care providers more often than men. 37 Therefore, PHPT may be underdiagnosed in men. Unfortunately, we cannot currently estimate the magnitude of such an effect, if any exists. Ballem et al 10 found that bone disease in PHPT is underappreciated, underdiagnosed and consequently undertreated in men. They determined that as DXA screening in men with PHPT became more
common, rates of bone disease detection rose to levels approaching those of women. Ballem et al 10 also found that women had significantly higher rates of follow-up BMD screening than men (P < 0.001) and that men were 4 times less likely than women to continue experiencing bone loss after PTX.
The greater bone density increase observed in men after PTX cannot be attributed to variations in estrogen levels. We found no difference in the percentage of change in BMD values after PTX in pre-MP and post-MP women, suggesting that differences in estrogen levels do not explain the observed patterns of BMD recovery after PTX. Increased body mass index (BMI) can lead to higher estrogen levels in both men and women. As our study groups had similar BMIs (between men, all women, pre-MP and post-MP), there was no additional reason for the lower preoperative Z-scores appreciated in men, or the greater increases of BMD after PTX noticed in men.
Taken together, studies suggest that PTX itself has a direct impact on the restoration of bone mineralization. Moreover, the beneficial effect of PTX in pre-MP women with reduced BMD indicates that surgical cure of PHPT has an additive effect on BMD even when abundant estrogen is present. 25 Patterns of degeneration of the cancellous bone vary according to gender. In women, rapid accelerated bone loss takes place 5 years after menopause, which then slows but continues throughout the postmenopausal years. In men, cancellous bone loss occurs gradually and much later in life, especially after the age of 70 years. 38 Statistical analysis was run again after removing the 10 women that underwent PTX within 5 years after menopause to ensure that the greater BMD increase appreciated in men was not caused by the presence of these specific women population.
New analysis showed no change compared to prior results (data not shown).
Androgens help to form the skeleton of young men and prevent bone loss in elderly men. As bioavailable testosterone levels decrease later in life, the incidence of osteoporotic fractures in men increases exponentially. Both androgens and estrogen enhance bone formation by stimulating proliferation of preosteoblasts and differentiation of osteoblasts to enhance bone formation, but only estrogen acts in suppressing bone resorption. This is when aromatization of testosterone to estradiol becomes crucial for bone health in men. 38 Interestingly, Almqvist et al 39 found that higher free testosterone levels after PTX are associated with higher hip and lumbar spine BMD in post-MP women. The authors suggested that PHPT causes relative androgen deficiency mediated by an increase in circulating sex hormone binding globulin.
Given that the kidneys are susceptible to end organ damage in patients with PHPT, we assessed renal-related differences among our patient groups. Preoperative 24-hour urinary calcium excretion levels were higher in men than in women, including post-MP women. Ballem et al 10 and Mazeh et al 2 documented similar results, with preoperative 24-hour urinary calcium levels being higher in men. Interestingly, both of these studies, which focused on gender differences in clinical presentation, noted that nephrolithiasis was more frequent in men than in women. These findings are compatible with rates found in the general population, in which the incidence and prevalence of nephrolithiasis are between 2 and 4 times higher in men than in women. 2, 36 This difference is also observed in patients with PHPT, and it may be increased in the setting of hypercalciuria. Dy et al 25 noted that preoperative urinary calcium levels were higher in patients who experienced significant improvement after PTX. We suggest that the excess urinary calcium in these patients comes primarily from the bone, causing more severe bone disease but, as supported by Dy et al, 25 leads to greater improvements in BMD after PTX.
We attribute the better BMD recovery in men to their more severe bone disease at presentation (lower preoperative Z-scores) and higher preoperative urinary calcium levels than women; and thus, our data support previous suggestion by Sharma et al 8 and Dy et al 25 that more advanced bone loss and higher urinary calcium excretion create a greater opportunity for improved BMD after PTX.
Our study was unique in several respects. First, we divided the population of women by MP status. Second, we used preoperative Z-scores instead of T-scores to avoid age bias. Third, all patients in our study cohort were free of medications that interfere with calcium and/or bone metabolism. Finally, all patients' preoperative and postoperative DXA scans were performed at our institution, reducing the effect of apparatus or operator differences.
Our work has the limitations expected of a retrospective study.
Despite the large initial cohort, only 80 patients met our inclusion criteria, which were made strict in an effort to minimize the number of confounders. Unfortunately, the use of such stringent inclusion criteria, along with the single-institution study design, may have introduced selection bias. In addition, the statistical power to detect differences among subgroups is reduced in a small sample. Another limitation of this study is that complete laboratory analyses were not available for all patients. In addition, data on other factors that affect bone metabolism, such as physical activity, diet, smoking history and alcohol intake history, were not assessed. In light of these limitations, further studies are needed, including a multicentre prospective study comparing BMD gender differences in BMD using the Fracture Risk Assessment Tool (FRAX-score), which was not utilized in this study. It is an interesting point to consider that the FRAX risk for men in our study could have potentially been lower than that of women despite the lower preoperative Z-scores noted in men.
Because the decision to undergo PTX is ultimately made by the patient, physicians have the responsibility to deliver the most complete information to patients. Although some patients may not be concerned by hypercalcemia, the risk of sustaining a spontaneous hip fracture is likely to cause concern. Patients with PHPT should be informed about the benefit of PTX in improving bone density, as evidenced in the present study. DXA screening is crucial for identifying patients who need additional treatment for their bone disease (eg bisphosphonate, denosumab) even after undergoing PTX.
Furthermore, for those asymptomatic patients a documented BMD improvement could encourage routine follow-up medical evaluation.
In conclusion, our study showed that men had a greater significant BMD increase at the femoral neck compared with women after PTX. Beyond treatment of hypercalcemia and reduction of nephrolithiasis incidence, this amount of improved BMD could translate to reduction of risk for fracture in the male population.
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